Clinical Trial

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-03; most recent amendment 2026-03-02.
Status change: Suspended → Recruiting 2026-03-02
Status change: Not Yet Recruiting → Suspended 2026-02-13
Trial Details
NCT Number NCT07065630
Lead Sponsor University of Chicago
Conditions Head and Neck Cancer, HPV
Enrollment 38 participants
Start Date 2025-10-07
Primary Completion 2029-08-13 (estimated)
Study Completion 2029-08-13 (estimated)
Updated on ClinicalTrials.gov 2026-03-04